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The prevalence of HIV-infected people aged 50 years or older is increasing rapidly; the proportion will increase from 28% to 73%
in 2030. In addition, HIV-infected individuals may be more vulnerable to age-related condition.There is growing evidence that the
prevalence of comorbidities and other age-related conditions (geriatric syndromes, functional or neurocognitive/mental problems,
polypharmacy, and social difficulties) is higher in the HIV-infected population than in their uninfected counterparts. However,
despite the potential impact of this situation on health care, little information exists about the optimal clinical management of older
HIV-infected people. Here we examine the age-related conditions in older HIV-infected persons and address clinical management
according to author expertise and published literature. Our aim is to advance the debate about the most appropriate management
of this population, including less well-studied aspects, such as frequency of screening for psychological/mental and social and
functional capabilities.
1. Introduction
Our society is aging at an unprecedented rate. People aged 65
and older make up 17% of the population, and by 2030, when
the youngest baby boomers turn 65, an estimated 26% of the
population could be considered “elderly” [1].
The prevalence of HIV-infected people aged 50 years
or older is also increasing rapidly. According to data from
the Dutch ATHENA cohort, the proportion of adults aged
50 and older will increase from 28% in 2010 to 73% in
2030 [2]. In addition, HIV-infected individuals may be more
vulnerable to age-related conditions [3, 4]. This population
often exhibits a higher number of comorbidities and other
age-related conditions at a younger age than in the general
population [4–9].
Age-associated inflammation, or “inflammaging,” is a
major risk factor for both morbidity and mortality in older
adults [10]. Chronic inflammation not only impacts the
functioning of the immune system, but also contributes to
an increased prevalence of many diseases in the general
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aging process, including cardiovascular disease, diabetes, and
cancers. When immune function declines, chronic infections
(including CMV and HIV) may be reactivated, stimulate
the innate immune system, and trigger a subclinical inflam-
matory response that, in turn, stimulates adaptive immune
responses, thus creating a vicious circle. AmongHIV-infected
individuals, the presence of subclinical chronic inflammation
related to HIV infection is also associated with major age-
related complications [11] and has been linked to a decreased
survival among these patients [12].
Despite the heterogeneous nature of the aging process,
common health characteristics of older adults include mul-
tiple comorbidities, geriatric syndromes (falls, incontinence,
frailty, dementia, confusion, malnutrition, sarcopenia, and
disability), polypharmacy, social difficulties (e.g., isolation,
poverty, and lack of caregivers), and atypical clinical presenta-
tions of common health conditions (e.g., depression without
sadness, infection without fever or leukocytosis, and acute
coronary or acute abdominal syndrome without pain). Older
patients often experience more than one geriatric syndrome
or manifestations of aging, as there is a large overlap between
the aetiological factors.
Despite the potential impact of this situation on health
care, the optimal clinical management of older HIV-infected
people is not well defined.We examine the age-related condi-
tions in older HIV-infected persons and provide suggestions
on clinicalmanagement according to published literature and
guidelines [13], as well as the expertise of the authors. Our
aim is to advance the debate about the most appropriate
management of older HIV-infected individuals.
The observations we make are not focused on specific
comorbidities, which have received considerable attention
and may have separate published guidelines. Rather, our
objective is to address integration of various guidelines in
addition to less well-studied aspects.
2. Clinical Conditions
With the aging of the HIV-infected population, the burden
of noncommunicable diseases or HIV-associated non-AIDS
conditions has been increasing steadily [3–9, 14]. From 2003
to 2013, the US Medicaid Database reported an increasing
prevalence of CVD (3% to 7%), renal impairment (5% to 11%),
osteoporosis (4% to 6%), and diabetes mellitus (9% to 19%)
[15]. As a result, non-AIDS-related mortality has eclipsed
AIDS-related mortality as the major cause of death in HIV-
infected persons with widespread access to antiretroviral
therapy [16–18].
In addition, there is growing evidence that the prevalence
of these comorbidities and other age-related conditions
(functional or neurocognitive/mental problems) is higher
in the HIV-infected population than in their uninfected
counterparts [19].
2.1. Comorbidities. The increased prevalence of CVD in this
group reflects the complex interaction between age-related
factors of this population: the high prevalence of classic
cardiovascular risk factors (tobacco use, dyslipidaemia, dia-
betes, recreational drug use, etc.), the inflammatory status,
and the effects of HIV replication and antiretroviral therapy
[20, 21]. HIV infection itself, as well as the impact of HIV
on gut permeability, resulting in bacterial translocation,
may lead to the development of accelerated atherosclerosis
and decreased high-density lipoprotein (HDL) levels [22].
Additionally, proinflammatory populations of T cells and
activated monocytes may lead to functional or structural
vascular changes linked with the development of coronary
plaques [23].
Guidelines for the screening of CVD in the setting of HIV
infection largely follow recommendations for the general
population [24]. However, both the Framingham risk score
and the 2013 American College of Cardiology/American
Heart Association (ACC/AHA) guidelines have been shown
to underestimate the CVD risk in this population [25].
Current recommendations to reduce CVD risk are mainly
focused on the viral suppression and the appropriate man-
agement of traditional risk factors. Special emphasis is placed
on cigarette smoking; the high prevalence of smokers among
the HIV-infected population urges the inclusion of smoking
treatment protocols in current models of HIV care. Future
and ongoing studies such as the REPRIEVE study (the use
of pitavastatin to reduce the risk of CVD in HIV-infected
adults) will inform future decisions about how to manage
cardiovascular risk factors and reduce systemic inflammation
(e.g., using statins).
Chronic kidney disease (CKD) is also more common
in patients with chronic HIV infection than in the general
population [26]. CKD accounts for significant morbidity and
mortality in 30% of HIV-infected individuals [27]. Other
common risk factors include increasing age, hyperlipidaemia,
diabetes, exposure to some antiretroviral drugs, and hepatitis
B and hepatitis C. Concomitant bone disease is also an
emerging comorbidity. The prevalence of osteopenia and
osteoporosis is increased in HIV-infected persons (up to
60% and 10–15%, resp.), although the mechanism and con-
sequences of these changes are not fully understood [28].
Screening and assessment of bone disease is thoroughly
described in the European AIDS Clinical Society (EACS)
guidelines [29] and other guidelines for the management of
bone disease [30].
As the incidence of cancer increases exponentially with
age, it is expected that the number of patients with con-
current malignancies will increase. Indeed, HIV infection
predisposes to several types of cancer, in particular those
associated with chronic viral infections such as Epstein-
Barr virus (non-Hodgkin lymphoma), human herpes virus 8
(Kaposi’s sarcoma), hepatitis B and C viruses (hepatocellular
carcinoma), and human papillomavirus (cervical intraep-
ithelial neoplasia and anal intraepithelial neoplasia) [31, 32].
At present, there are no specific data regarding whether
the clinical presentation is altered in HIV-infected patients
or whether management of cancer in HIV-infected aging
patients should differ from standard screening protocols.
2.2. Neurocognitive Impairment. HIV-associated neurocog-
nitive disorder (HAND) covers a spectrum of neurocogni-
tive impairment, from asymptomatic neurocognitive impair-
ment and mild neurocognitive disorder to HIV-associated
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dementia (HAD). HAND includes a variety of cognitive
symptoms, such as problems in attention/working memory,
learning/memory, executive function, and processing speed.
There is consistent evidence that neurocognitive ability
is commonly impaired in HIV-infected patients; about half
of all antiretroviral-treated patients present with cognitive
impairment. Advanced age increases susceptibility to HAND
in HIV-infected individuals, leading to alteration of the
presentation of HAND and an increase in the proportion
of older HIV-infected adults with HAD. Although greater
neuropsychological impairment affects older HIV-infected
persons more frequently than younger infected individuals,
many middle-aged HIV-infected individuals are also experi-
encing cognitive decline similar to that found in much older
non-HIV-infected adults [33].
Direct damage caused by the virus, as well as indirect
factors (e.g., increased risk of CVD, chronic drug use/abuse,
and potentially toxic long-term antiretroviral use), has a
synergistic negative effect on the central nervous system
[34]. Persistent inflammatory response and neuroimmuno-
logical disorders, vascular and metabolic comorbidities, and
neurotoxicity have been identified as potential causes of
neural injury in the olderHIV-infected population. Common
neuroimaging findings in HIV-infected persons, particularly
among older adults, include brain atrophy (cortical and
subcortical), elevations in abnormal white matter signal on
magnetic resonance, metabolic abnormalities, and variations
in regional glucose metabolism. These trends in neuropsy-
chological and neuroimaging data point to the significance
of an interaction of HIV with the aging brain. However,
it is still unknown whether this interaction directly affects
neurodegenerative processes, accelerates normal cognitive
aging, or contributes to other comorbidities affecting the
brain in older adults [33].
Of particular concern for researchers, clinicians, and
patients is the decline in everyday functioning (e.g., instru-
mental activities) that is observed in a significant proportion
of adults with HIV and is clearly more prominent among
older adults. Older HIV-infected patients are particularly
vulnerable to decline in everyday functioning, mainly in
instrumental activities. These findings are not surprising,
because neuropsychological functioning is predictive of
impairment in everyday functioning. Cognitive impairment
may be detrimental to the real-world functioning of older
HIV-infected adults and could potentially interfere in basic
activities such as antiretroviral adherence or ability to drive.
Assuming the clinical relevance and public health impact
of neuropsychological impairment on older HIV-infected
adults, there is a growing need to identify factors associated
with successful cognitive aging (e.g., cognitive reserve and
lifestyle).
In addition, a systematic and appropriate neuropsy-
chological evaluation of older adults with HIV should be
incorporated into clinical practice to identify patients with
cognitive impairment, predict their functional capacity, and
determine the best potential therapeutic approach for delay-
ing or reducing the impact of cognitive impairment [34].The
age-related cognitive decline amongHIV-uninfected subjects
can be partially reduced by mental training and physical
activity [35] (Figure 1). Similar considerations should be given
to treating age-associated cognitive decline in HIV-infected
persons.
2.3. Functional Limitations and Frailty. In the geriatrics
literature, the well-described frailty phenotype is regarded as
a loss of functional homeostasis that leaves a person unable
to effectively recover from various stressors and is associated
with poor health outcomes, including excess mortality [36].
Ultimately, the cumulative burden of comorbidities and their
respective therapies, as described above, may lead to frailty
in HIV-infected persons. Indeed, based on a variety of
definitions, the prevalence of frailty or a frailty-like syndrome
has been reported in 5–19% of HIV-infected cohorts [37].
Initial studies among HIV-infected populations describe the
higher prevalence of frailty in persons with the deepest
immune compromise, and subsequent studies have contin-
ued to demonstrate an association between HIV serostatus
and frailty, regardless of effective antiretroviral therapy [38–
42]. In addition to the syndrome of frailty, impairment in
objective measures of physical function is also apparent.
Compared with demographically similar non-HIV-infected
adults, HIV-infected persons appear to experience early
impaired physical function [43] that ranges frommore subtle
impairments at a high level of functioning, such as lower peak
exercise capacity [44], to more severe impairments such as
difficulty completing a quarter-mile walk or a short physical
performance battery [45–47].
The clinical consequences of these impairments in phys-
ical function and frailty are readily apparent: impaired phys-
ical function and frailty have been associated with increased
risk of insulin resistance [48], falls [49], impaired quality
of life [50], and hospitalizations [45, 51]. Furthermore, the
cooccurrence of both HIV infection and impaired physical
function or frailty has a synergistic effect: in the ALIVE
cohort, predicted mortality was significantly greater with the
combination of both HIV and impaired physical function
than with HIV infection or impaired physical function alone
[46]. Similarly, the impact of both HIV infection and frailty
also had a synergistic effect on mortality [52].
In the HIV-uninfected population, only a small propor-
tion of frail individuals will return spontaneously to full
robustness [53]. Interventions aimed at increasing physical
activity and improving nutrition have been shown to be
effective [54–56]. While evaluation of physical function and
frailty is not routinely assessed in most HIV clinics, simple
measures such as gait speed on 4-meter walk, time to rise
from a chair, and grip strength could provide clinically
relevant data [43, 57] (Figure 1). Repeat measurements can
advance understanding of the underlying causes (e.g., HIV,
age, and comorbidities) and guide interventions to prevent,
slow, or reverse impairments and frailty.
3. Polypharmacy and Drug-Drug Interactions
The development of comorbidities in older HIV-infected
patients often results in initiation of new treatments, in
addition to ongoing antiretroviral treatment. Consequently,
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BMI: body mass index
CVD: cardiovascular disease
STIs: sexually transmitted infections
QoL: quality of life
Medical visit
(at least twice per year)
Medical history:
Check medical
problems,
hospitalizations,
allergies, adverse events,
substance use, sexual
habits
Centralized medication
history:
Check prescription
medications, over-the-
counter and alternative
remedies
Physical examination:
Routine blood/urine
test, including viral load
and CD4/CD8 T cells
when required
Special approaches
(at least annually)
Age-appropriate
assessment of
comorbidities (e.g.,
[23, 28, 29]
Evaluation of geriatric
syndromes (falls,
incontinence, sleep
disorders, confusion,
vision/hearing
problems,
Update vaccines
Nutritional assessment
Screen for hepatitis C/B
and other STIs
Physical function/
frailty measurements
to rise from a chair, or
grip strength) [42]
Neuropsychological
and psychological
evaluation (e.g.,
depressive symptoms,
QoL,
neuropsychological
test) [33]
Evaluation of social
problems
Key actions
Prevent chronic conditions or
ensure early detection and
control [13]
Check drug-drug
interactions
Stop unnecessary drugs
(STOP/START criteria)
[63, 64]
Choose the most appropriate
antiretroviral regimen
according to the patient’s
conditions [80, 81]
Reduce risk factors and
encourage healthy behaviours
[13]. Counseling on diet and
physical activity
Maintain muscle mass
and bone density
through exercise and
nutrition [13]
Treat the underlining
causes of declines in
capacity [13]
Intervention for sensory and
physical problems
Cognitive remediation if
neurocognitive impairment
[33, 34]
Psychologist/psychiatry if
psychological problems (e.g.,
anxiety, depression)
Social workers if social
problems
Capacity enhancing
behaviours,
strengthening personal
skills, and building
relationships [13]
Vital signs, BMI. . .
cancer, CVD, bone)
sarcopenia,. . .)
(e.g., 4Ｇ walk, time
Figure 1:General and specific considerations for older HIV-infected subjects. CVD, cardiovascular disease; STIs, sexually transmitted infections;
QoL, quality of life.
older HIV-infected patients tend to use a higher number
of concomitant medications, especially cardiovascular thera-
pies, central nervous system agents, and medications to treat
gastrointestinal disorders [58]. For example, 14% of patients
aged more than 65 years in the Swiss HIV Cohort Study were
taking 4 or more concomitant medications [59].
The term “polypharmacy” is used to describe consump-
tion of multiple (usually considered more than 5), excessive,
unnecessary, or nonindicated drugs [60]. Complex treatment
containing a high number of drugs is associated with a
greater likelihood of medication errors and lack of adherence
[61]. In addition, polypharmacy may cause adverse effects,
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particularly in older patients with underlying comorbidities
and altered drug metabolism [62, 63]. Finally, concomitant
use of multiple drugs may result in drug-drug interactions,
which can further impact treatment safety, efficacy, and
adherence [58]. According toMarzolini et al. [58], nearly half
of HIV-infected people aged 50 or older may be receiving
concomitant drugs that are potentially prone to significant
interactions with antiretroviral therapy, especially when the
antiretroviral regimen included boosted antiretroviral drugs.
Interactions with antiretroviral drugs are driven mainly
by induction or inhibition of enzymes and transporters
involved in drug disposition [60]. Ritonavir and cobicistat
are both potent inhibitors of the enzyme CYP3A4 and
of drug transporters in the gut and liver. Consequently,
use of boosted protease or integrase inhibitors may be
associated with increased exposure to a large number of
concomitant agents (e.g., hypnotics, antidepressants, lipid-
lowering agents, antiarrhythmics, and corticosteroids), even-
tually leading to a high risk of adverse effects. Conversely,
efavirenz and etravirine can induce the activity of enzymes
and transporters, leading to subtherapeutic concentrations of
other drugs in some cases. Finally, the unboosted integrase
inhibitors raltegravir and dolutegravir seem to be associated
with a lower risk of interactions with other drugs.
Antiretroviral drugs may be both perpetrators and vic-
tims of interactions if they are combined with other enzyme
inducers (e.g., rifampin, older antiepileptics) or inhibitors
(e.g., antifungals). Additionally, the absorption of some
antiretrovirals may be altered by other medications through
chelation of divalent cations (e.g., integrase inhibitors) and
through changes in gastric pH (e.g., atazanavir, rilpivirine).
Management of polypharmacy in the older people can be
complex, especially when multiple prescribers are involved
in patient care [60]. A centralized medication history is
mandatory and should include not only prescription med-
ications but also over-the-counter and alternative remedies
(e.g., herbals, supplements) (Figure 1). A critical review of
the therapeutic regimen should be made at every patient
visit, and unnecessary drugs should be stopped (Beers and
STOPP/STARTcriteria) [64, 65]. Finally, specific information
on drug-drug interactions should be consulted (Figure 1).
Ideally, sources of information on drug-drug interactions
should be widely accessible, provide accurate and easy-
to-interpret information about the clinical management of
these interactions, and undergo regular updates (excellent
examples include https://www.hiv-druginteractions.org/ and
http://app.hivclinic.ca/). Providers should maintain a proac-
tive approach towards drug-drug interactions and anticipate
potential drug-drug interactions both when prescribing a
new drug and when deciding to discontinue a drug.
4. Clinical Considerations for the Care of
Older HIV-Infected Adults
General care of older HIV-infected adults should be based
both uponHIV-related conditions and upon other conditions
specifically related to the older adult.
4.1. Antiretroviral Treatment. The specific antiretroviral reg-
imens for older adults are not different from those recom-
mended for the general HIV-infected population. However,
the choice of regimen and potential adverse reactions or
drug-drug interactions should be evaluated carefully based
on the presence of comorbidities and respective treatments.
Tenofovir disoproxil fumarate (TDF) has been associated
with an increased risk of chronic kidney disease [66] and
higher prevalence of osteopenia and osteoporosis [67]. The
recently approved agent tenofovir alafenamide (TAF) appears
to be associated with less kidney disease and less reduction in
bone mineral density [68].
Some antiretroviral regimens have been associated with
an increase in cardiovascular risk. For example, in the D:A:D
cohort study, a significantly increased risk of CVD was
detected in patients exposed to indinavir, lopinavir-ritonavir,
didanosine, and abacavir [69] andmore recently to darunavir
[70]. Subsequent studies on the potential association between
abacavir and CVD are contradictory [71, 72] and randomized
clinical trials [73] and meta-analyses on this topic have not
confirmed this association [74, 75]. However, many guide-
lines recommend caution using abacavir based therapies
in patients with underlying cardiovascular disease if other
options are available [35, 76].
Because of possible nucleoside/nucleotide reverse tran-
scriptase inhibitor- (NRTI-) related toxicities and drug-drug
interactions, especially in older persons, new therapeutic
regimens are being investigated. These include dual class
therapy with protease inhibitors and integrase inhibitors
[77] or lamivudine [78] and NRTI- and protease inhibitor-
sparing regimens (e.g., dolutegravir-based dual therapy) [79,
80]. Although the treatments appear promising in initial
trials with younger populations, long-term durability in older
adults has not yet been established. Concomitantmedications
(calcium, iron, vitamins)may interfere with the absorption of
integrase inhibitors; therefore, careful attention is imperative
with these regimens.
Based on the presence of comorbidities, polypharmacy,
and pharmacokinetic and pharmacodynamic alterations
associated with age, Guaraldi [81] further expanded consid-
erations in the choice of antiretroviral drug for these patients,
with an emphasis on integrase inhibitors [82], owing to
their tolerability, low toxicity, and low number of drug-drug
interactions. However, given that multiple treatment options
are available, treatment should be prescribed on an individual
basis, informed by underlying resistance, comorbidities, and
patient and provider preference.
Finally, until recently, HIV-infected patients over 50
years of age have been poorly represented in clinical trials;
consequently, complications and toxicities may be underre-
ported in this collective [83]. Clinical and pharmacokinetic
trials with HIV-infected persons aged more than 50 years
are essential [84–86]; ongoing trials will provide us with
invaluable data.
4.2. General Considerations:Next Steps. Theneeds of an aging
population are emphasized in theWorldHealthOrganization
definition of health: “Health is a state of complete physical,
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mental and social well-being and not merely the absence of
disease or infirmity.” In older adults, the medical, physical,
mental, and social aspects of health could be assessed using
a comprehensive geriatric assessment (CGA) to ascertain
health status and individual needs [87, 88]. CGA is a multi-
dimensional, interdisciplinary diagnostic process that makes
it possible to determine the medical, psychological, and
functional capabilities of an older person by using specific
criteria including age, medical comorbidities, psychosocial
problems, previous or predicted high health care utilization,
change in living situation, and specific geriatric conditions.
It is mainly focused on determining the pathological risk,
residual skills, short- and long-term prognosis, and the
personalized therapeutic and care plan of the functionally
compromised and frail older subjects. A systematic review
of data coming from the last three decades about the sys-
tematic implementation of CGA programs evidences that
mainly complex older subjects may benefit from a CGA, by
improving quality of care and reducing hospitalization events
[88].
AmongHIV-infected persons aged 50 years or older, both
general and HIV-specific management considerations can be
taken into account and CGA programs should be considered
to be incorporated in the HIV clinics in the following years
[89, 90]. Figure 1 summarizes some considerations. Of note,
these multiple considerations for the older adult with HIV
infection should be individualized and prioritized dependent
on the care goals of the individual patient.
In summary, aging is a complex process that is more
complicated in combination with a chronic disease, such
as HIV infection. The geriatric literature suggests that care
of the older patient with multimorbidity is best managed
with the assistance of a multidisciplinary team. HIV medical
care providers caring for older HIV-infected patient with
multimorbidity can be guided by these principles of geriatric
medicine. Providers should seek to understand the future
health needs of older HIV-infected patients and modify the
goals of care to meet these needs.
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